Free Access
Med Sci (Paris)
Volume 24, Number 8-9, Août-Septembre 2008
Page(s) 735 - 741
Section M/S revues
Published online 15 August 2008
  1. Deltour S, Chopin V, Leprince D. Modifications épigénétiques et cancer. Med Sci (Paris) 2005; 21 : 405–11. [Google Scholar]
  2. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2 (suppl 1) : S4–11. [Google Scholar]
  3. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37 : 391–400. [Google Scholar]
  4. Govin J, Escoffier E, Rousseaux S, et al. Pericentric heterochromatin reprogramming by new histone variants during mouse spermiogenesis. J Cell Biol 2007; 176 : 283–94. [Google Scholar]
  5. Wallace JA, Felsenfeld G. We gather together: insulators and genome organization. Curr Opin Genet Dev 2007; 17 : 400–7. [Google Scholar]
  6. Loukinov DI, Pugacheva E, Vatolin S, et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 2002; 99 : 6806–11. [Google Scholar]
  7. Vatolin S, Abdullaev Z, Pack SD, et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65 : 7751–62. [Google Scholar]
  8. D’Arcy V, Abdullaev ZK, Pore N, et al. The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res 2006; 12 : 5978–86. [Google Scholar]
  9. D’Arcy V, Pore N, Docquier F, et al. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 2008; 98 : 571–9. [Google Scholar]
  10. Kholmanskikh O, Loriot A, Brasseur F, et al. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008; 122 : 777–84. [Google Scholar]
  11. Risinger JI, Chandramouli GV, Maxwell GL, et al. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 2007; 13 : 1713–9. [Google Scholar]
  12. Hong JA, Kang Y, Abdullaev Z, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65 : 7763–74. [Google Scholar]
  13. Kang Y, Hong JA, Chen GA, et al. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 2007; 26 : 4394–403. [Google Scholar]
  14. Kondo T, Zhu X, Asa SL, Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007; 13 : 4713–20. [Google Scholar]
  15. Yang B, Wu J, Maddodi N, et al. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J Invest Dermatol 2007; 127 : 2123–8. [Google Scholar]
  16. Yang B, O’Herrin SM, Wu J, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007; 67 : 9954–62. [Google Scholar]
  17. Monte M, Simonatto M, Peche LY, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006; 103 : 11160–5. [Google Scholar]
  18. Laduron S, Deplus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 2004; 32 : 4340–50. [Google Scholar]
  19. Shang E, Nickerson HD, Wen D, et al. The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 2007; 134 : 3507–15. [Google Scholar]
  20. Scanlan MJ, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000; 150 : 155–64. [Google Scholar]
  21. Gokul G, Gautami B, Malathi S, et al. DNA Methylation profile at the DNMT3L promoter: A potential biomarker for cervical cancer. Epigenetics 2007; 2 : 80–5. [Google Scholar]
  22. Ooi SK, Qiu C, Bernstein E, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007; 448 : 714–7. [Google Scholar]
  23. Baudat F, de Massy B. SPO11 : une activité de coupure de l’ADN indispensable à la méiose. Med Sci (Paris) 2004; 20 : 213–8. [Google Scholar]
  24. Kisseleva-Romanova E, Lopreiato R, Baudin-Baillieu A, et al. Yeast homolog of a cancer-testis antigen defines a new transcription complex. EMBO J 2006; 25 : 3576–85. [Google Scholar]
  25. Park JH, Lin ML, Nishidate T, et al. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006; 66 : 9186–95. [Google Scholar]
  26. Dodge JE, Kang YK, Beppu H, et al. Histone H3-K9 methyltransferase ESET is essential for early development. Mol Cell Biol 2004; 24 : 2478–86. [Google Scholar]
  27. Tachibana M, Ueda J, Fukuda M, et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev 2005; 19 : 815–26. [Google Scholar]
  28. Collins RE, Tachibana M, Tamaru H, et al. In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases. J Biol Chem 2005; 280 : 5563–70. [Google Scholar]
  29. D’Alessio AC, Weaver IC, Szyf M. Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes. Mol Cell Biol 2007; 27 : 7462–74. [Google Scholar]
  30. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5’ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004; 24 : 4781–90. [Google Scholar]
  31. Loriot A, De Plaen E, Boon T, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006; 281 : 10118–26. [Google Scholar]
  32. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006; 25 : 6975–85. [Google Scholar]
  33. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 : 1643–7. [Google Scholar]
  34. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92 : 11810–3. [Google Scholar]
  35. Scanlan MJ, Gordon CM, Williamson B, et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002; 98 : 485–92. [Google Scholar]
  36. Bock-Axelsen J, Lotem J, Sachs L, Domany E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci USA 2007; 104 : 13122–7. [Google Scholar]
  37. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4 : 1–15. [Google Scholar]
  38. Kalejs M, Erenpreisa J. Cancer/testis antigens and gametogenesis: a review and brain-storming session. Cancer Cell Int 2005; 5 : 4. [Google Scholar]
  39. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5 : 615–25. [Google Scholar]
  40. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007; 25 : 707–11. [Google Scholar]
  41. Condomines M, Hose D, Raynaud P, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 2007; 178 : 3307–15. [Google Scholar]
  42. Meklat F, Li Z, Wang Z, et al. Cancer-testis antigens in haematological malignancies. Br J Haematol 2007; 136 : 769–76. [Google Scholar]
  43. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94 : 1914–8. [Google Scholar]
  44. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007; 104 : 12837–42. [Google Scholar]
  45. Susumu S, Nagata Y, Ito S, et al. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Sci 2008; 99 : 107–12. [Google Scholar]
  46. Gabory A, Dandolo L. Épigénétique et développement : l’empreinte parentale. Med Sci (Paris) 2005; 21 : 390–5. [Google Scholar]
  47. Laget S, Defossez PA. Le double jeu de l’épigénétique : cible et acteur du cancer. Med Sci (Paris) 2008; 24 : 725–30. [Google Scholar]
  48. Weber M. Profils de méthylation de l’ADN dans les cellules normales et cancéreuses. Med Sci (Paris) 2008; 24 : 731–4. [Google Scholar]
  49. Henckel A, Feil R. Asymétrie des génomes parentaux : implications en pathologie. Med Sci (Paris) 2008; 24 : 747–52. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.